Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04325061
Other study ID # 2020-001278-31
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date April 3, 2020
Est. completion date June 19, 2020

Study information

Verified date February 2021
Source Dr. Negrin University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: There are no proven therapies specific for Covid-19. The full spectrum of Covid-19 ranges from asymptomatic disease to mild respiratory tract illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and death. The efficacy of corticosteroids in viral ARDS remains controversial. Methods: This is an internationally (Spain, Canada, China, USA) designed multicenter, randomized, controlled, open-label clinical trial testing dexamethasone in mechanically ventilated adult patients with established moderate-to-severe ARDS caused by confirmed Covid-19 infection, admitted in a network of Spanish ICUs. Eligible patients will be randomly assigned to receive either dexamethasone plus standard intensive care, or standard intensive care alone. Patients in the dexamethasone group will receive an intravenous dose of 20 mg once daily from day 1 to day 5, followed by 10 mg once daily from day 6 to day 10. The primary outcome is 60-day mortality. The secondary outcome is the number of ventilator-free days at 28 days. All analyses will be done according to the intention-to-treat principle.


Description:

The acute respiratory distress syndrome (ARDS) is a catastrophic illness of multifactorial etiology characterized by a diffuse, severe inflammatory process of the lung leading to acute hypoxemic respiratory failure requiring mechanical ventilation (MV). Pulmonary infections are the leading causes of ARDS. Clinical and experimental research has established a strong association between dysregulated systemic and pulmonary inflammation and progression or delayed resolution of ARDS. The COVID-19 pandemic is a critical moment for the world. Severe pneumonia is the main condition leading to ARDS requiring weeks of MV with high mortality (40-60%) in COVID-19 patients. There is no specific therapy for Covid-19, although patients are receiving drugs that are already approved for treating other diseases. There has been great interest in the role of corticosteroids to attenuate the pulmonary and systemic damage in ARDS patients because of their potent anti-inflammatory and antifibrotic properties. However, the efficacy of corticosteroids in viral ARDS remains controversial. We justify the need of this study based on the positive results of a recent clinical trial by our group, showing that dexamethasone for 10 days was able to reduce the duration of mechanical ventilation (MV) and increase hospital survival in patients with ARDS from multiple causes (Villar J et al. Lancet Respir Med 2020). Dexamethasone has never been evaluated in viral ARDS in a randomized controlled fashion. Our goal in this study is to examine the effects of dexamethasone on hospital mortality and on ventilator-free days in patients with moderate-to-severe ARDS due to confirmed COVID-19 infection admitted into a network of Spanish intensive care units (ICUs).


Recruitment information / eligibility

Status Terminated
Enrollment 19
Est. completion date June 19, 2020
Est. primary completion date June 19, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - age 18 years or older; - positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay for COVID-19 in a respiratory tract sample; - intubated and mechanically ventilated; - acute onset of ARDS, as defined by Berlin criteria as moderate-to-severe ARDS,3 which includes: (i) having pneumonia or worsening respiratory symptoms, (ii) bilateral pulmonary infiltrates on chest imaging (x-ray or CT scan), (iii) absence of left atrial hypertension, pulmonary capillary wedge pressure <18 mmHg, or no clinical signs of left heart failure, and (iv) hypoxemia, as defined by a PaO2/FiO2 ratio of =200 mmHg on positive end-expiratory pressure (PEEP) of =5 cmH2O, regardless of FiO2. Exclusion Criteria: - Routine treatment with corticosteroids during the previous week irrespective of dose; - Corticosteroid use within the previous 24 h of more than 20 mg of dexamethasone or equivalent; - Patients with a known contraindication to corticosteroids; - Decision by a physician that involvement in the trial is not in the patient's best interest; - Pregnancy and breast-feeding; - Participation in another therapeutic trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dexamethasone
Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization

Locations

Country Name City State
Spain Department of Anesthesia, Hospital Universitario de Cruces Barakaldo Vizcaya
Spain Intensive Care Unit, Hospital Universitario de Cruces Barakaldo Vizcaya
Spain AVI, Hospital Clinic Barcelona
Spain Cardiac ICU, Hospital Clinic Barcelona
Spain Department of Anesthesia, Hospital Clinic Barcelona
Spain Hepatic ICU, Hospital Clínic Barcelona
Spain UVIR, Hospital Clinic Barcelona
Spain Intensive Care Unit, Hospital General de Ciudad Real Ciudad Real
Spain Hospital Universitario Dr. Negrin Las Palmas de Gran Canaria Las Palmas
Spain Department of Anesthesia, Hospital Universitario La Paz Madrid
Spain Department of Anesthesia, Hospital Universitario La Princesa Madrid
Spain Intensive Care Unit, Hospital Universitario Fundación Jiménez Díaz Madrid
Spain Intensive Care Unit, Hospital Universitario La Paz Madrid
Spain Intensive Care Unit, Hospital Universitario La Princesa Madrid
Spain Department of Anesthesia, Hospital Universitario Virgen de Arrixaca Murcia
Spain Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca Murcia
Spain Department of Anesthesia, Hospital Unversitario Montecelo Pontevedra
Spain ICU, Hospital Universitari Mutua Terrassa Terrassa Barcelona
Spain Anesthesia, Hospital General Universitario de Valencia Valencia
Spain Department of Anesthesia, Hospital Clinico Universitario Valencia
Spain Intensive Care Unit, Hospital Clinico Universitario Valencia
Spain Anesthesia, Hospital Universitario Río Hortega Valladolid
Spain Department of Anesthesia, Hospital Clínico Universitario Valladolid
Spain Intensive Care Unit, Hospital Universitario Río Hortega Valladolid

Sponsors (3)

Lead Sponsor Collaborator
Dr. Negrin University Hospital Consorcio Centro de Investigación Biomédica en Red, M.P., Li Ka Shing Knowledge Institute

Country where clinical trial is conducted

Spain, 

References & Publications (2)

Villar J, Belda J, Añón JM, Blanco J, Pérez-Méndez L, Ferrando C, Martínez D, Soler JA, Ambrós A, Muñoz T, Rivas R, Corpas R, Díaz-Dominguez FJ, Soro M, García-Bello MA, Fernández RL, Kacmarek RM; DEXA-ARDS Network. Evaluating the efficacy of dexamethason — View Citation

Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, Aguilar G, Alba F, González-Higueras E, Conesa LA, Martín-Rodríguez C, Díaz-Domínguez FJ, Serna-Grande P, Rivas R, Ferreres J, Belda J, Capilla L, Tallet A, Añón JM, Fernández RL, González-Mar — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 60-day mortality All-cause mortality at 60 days after enrollment 60 days
Secondary Ventilator-free days Number of ventilator-free days (VFDs) at Day 28 (defined as days being alive and free from mechanical ventilation at day 28 after enrollment, For patients ventilated 28 days or longer and for subjects who die, VFD is 0. 28 days
See also
  Status Clinical Trial Phase
Terminated NCT04715243 - Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) & Helmet NIV in COVID-19 ARDS Patients N/A